Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2008-01-29
2008-01-29
Bertoglio, Valarie (Department: 1632)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S023100
Reexamination Certificate
active
10798096
ABSTRACT:
Disclosed is a complex immuno-gene medical composition for activating NK cells to enhance a host immune system. The composition includes a plurality of cytokines, including Th1 and Th2 cytokines. Th2 cytokines antagonize TGF-β inhibiting NK cells to disable the inhibition of the immune system. Th1 cytokines activate NK cells in a host to enhance the host's ability to fight against tumor cells. By use of the complex immuno-gene medical composition, removal of tumor cells is expected.
REFERENCES:
Johnson-Saliba et al. (2001) Gene Therapy:optimising DNa delivery to the nucleus. Curr. Drug Targets 2:371-99.
Verma et al., Gene therapy-promises, problems and prospects. (1997) Nature. 389:239-242.
Shoji et al. (2004) Current Status of Delivery systems to improve Target Efficacy of Oligonucleotides. Curr. Pharm. Design 10:785-796.
Pfeifer and Varmus (2001) Gene Therapy: Promises and Problems Annu. Rev. Genomics Hum. Genet. 2:177-211.
Silver et al. (2000) Ly-49P Activates NK-Mediated Lysis by Recognizing H-2Dd1. J. Immunol. 165:1771-1781.
Borrego et al. (2001) Structure and function of major histocompatibility complex (MHC) class I specific receptors expressed on human natural killer (NK) cells. Mol. Immunol. 38:637-660.
Raulet et al. (2003) Roles of the NKG2D Immunoreceptor and its Ligands. Nature Reviews Immunol. 3:781-790.
Perez et al. (1998) Immunohistochemical study of the local inflammatory infiltrate in spontaneous canine transmissible venereal tumour at different stages of growth. Vet. Immunol. and Immunopath. 64:133-147.
Hsiao et al. (2002) Effect if tumor infiltrating lymphocytes on the expression of MHC molecules in canine transmissible venereal tumor cells. Vet. Immunol. and Immunopath. 87:19-27.
Suzuki, K et al., Journal of Leukocyte Biology, 69:531-537, Apr. 2001.
Sivori, S., et al., “Early expression of triggering receptors and regulatory role of 2B4 in human natural killer cell precursors undergoing in vitro differentiation”,PNAS, 99(7):4526-4531 (2002).
Tan, P., et al., “Enhancement of Natural Killer Activity by an Antibody to CD441”,The Journal of Immunology, 150(3):812-820 (1993).
Storset, A.K., et al., “NKp46 defines a subset of bovine leukocytes with natural killer cell characteristics”,Eur. J. Immunol., 34:669-676 (2004).
Chu Rea-Min
Hsiao Ya-Wen
Liao Kuang-Wen
Lin Ching-Yi
Bertoglio Valarie
National Taiwan University
Ostrolenk Faber Gerb & Soffen, LLP
LandOfFree
Complex immuno-gene medical composition for inhibiting tumor... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Complex immuno-gene medical composition for inhibiting tumor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Complex immuno-gene medical composition for inhibiting tumor... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3940702